

**“PROPOSED”  
MENINGOCOCCAL CONJUGATE VACCINE (MCV4)  
FOR SCHOOL YEAR 2015-2016**

PROPOSED REQUIREMENT WILL BE FOR 6<sup>TH</sup> AND 12<sup>TH</sup> GRADE ENTRY

6 <sup>th</sup> Grade Entry	Must show proof of receiving one dose of meningococcal conjugate vaccine (MCV4)
12 <sup>th</sup> Grade Entry	Must show proof of receiving two doses of meningococcal conjugate vaccine (MCV4) The second dose of MCV4 must be $\geq$ 16 years of age
	If the first dose of MCV4 was administered $\geq$ 16 years of age, then only 1 dose of MCV4 is required at 12 <sup>th</sup> grade entry

Two manufacturers for meningococcal conjugate vaccine (MCV4):  
Menactra by sanofi Pasteur  
Menveo by Novartis

Governor Quinn signed the law in August 2013; this must now go through administrative rule process, which includes 3 State Board of Health public hearings around the state and at least one 45 days comment period to address comments and concerns.

*Recommended Immunization Schedule for Persons Age 0 Through 18 Years - United States, 2013*

18 Months to 18 Years

Vaccine	18 mos	19-23 mos	2-3 yrs	4-6 yrs	7-10 yrs	11-12 yrs	13-15 yrs	16-18 yrs
Meningococcal - MCV4						←1 <sup>st</sup> dose→		booster

Range of recommended ages for all children

Range of recommended ages for catch-up immunization

**Routine vaccination:**

- Administer MCV4 vaccine at age 11–12 years, with a booster dose at age 16 years.
- Adolescents aged 11 through 18 years with human immunodeficiency virus (HIV) infection should receive a 2-dose primary series of MCV4, with at least 8 weeks between doses. See [MMWR 2011: 60:1018–1019](#).

**Catch-up vaccination:**

- Administer MCV4 vaccine at age 13 through 18 years if not previously vaccinated.

- If the first dose is administered at age 13 through 15 years, a booster dose should be administered at age 16 through 18 years with a minimum interval of at least 8 weeks between doses.
- If the first dose is administered at age 16 years or older, a booster dose is not needed.